CURE

FDA Approves Subcutaneous Keytruda in Adult and Pediatric Solid Tumors

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.
Managed Healthcare Executive

FDA Approves First Subcutaneous Version of Keytruda for Adults With Most Solid Tumors

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...
The American Journal of Managed Care

FDA Approves Use of Subcutaneous Pembrolizumab for NSCLC, Most Solid Tumors

The FDA approved the use of pembrolizumab (Keytruda; Merck) and berahyaluronidase alfa-pmph (Keytruda Qlex; Merck) for use in patients 12 years and older with solid tumor indications approved for the ...
Oncology Nursing News

Subcutaneous Pembrolizumab Is FDA Approved, Slashes Chair Time

Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median ...
Targeted Oncology

FDA Approves Subcutaneous Pembrolizumab for Solid Tumor Indications

The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...
SurvivorNet on MSN

FDA Approves New Subcutaneous (Under-the-Skin) Option for Keytruda: What It Means for Cancer Patients

The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option for patients. The subcutaneous form of Keytruda showed to deliver the same ...